We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




German Prefilled Syringe Manufacturer to Double Production Capability

By LabMedica International staff writers
Posted on 18 Oct 2015
Print article
Image: A Vetter aseptically pre-filled syringe (Photo courtesy of Vetter).
Image: A Vetter aseptically pre-filled syringe (Photo courtesy of Vetter).
A major manufacturer of pre-filled sterile syringes, cartridges, and vials will be investing approximately EUR 300 million to expand and upgrade its manufacturing facilities over an estimated five-year period.

Vetter (Ravensburg, Germany) has stated that the expansion of its "Ravensburg Vetter West" facility was designed to meet future customer expectations and regulatory requirements at an early stage, maintaining a level of manufacturing excellence that customers have come to expect from Vetter. Structural work for the facility enlargement, which will more than double its current capacity, had been completed with the site being on schedule to become fully operational in 2017.

Among Vetter's many products is the patented dual-chamber syringe. A freeze-dried (lyophilized) drug resides in one chamber; liquid in the other. Pushing the plunger mixes the two, reconstituting the drug. The technology prolongs shelf-life, facilitates accurate dosing, and enables patients to self-administer.

“We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges. Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers,” said Peter Soelkner managing director of Vetter.

Related Links:

Vetter 


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Crypto + Giardia One Step Combo Card Test
CerTest Crypto + Giardia
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II

Print article

Channels

Molecular Diagnostics

view channel
Image: RT-QuIC Prion, CSF is the only definitive antemortem clinical test of its kind that doesn’t involve a brain biopsy (Photo courtesy of Mayo Clinic)

CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia

Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years.... Read more

Immunology

view channel
Image: New insights into preterm infant immunity could inform care (Photo courtesy of 123RF)

New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.